-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Atuzabrutinib in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Atuzabrutinib in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Atuzabrutinib in Atopic Dermatitis (Atopic Eczema) Drug Details: Atuzabrutinib (PRN-473)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Nemtabrutinib in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nemtabrutinib in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nemtabrutinib in Diffuse Large B-Cell Lymphoma Drug Details: Nemtabrutinib (ARQ-531)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Nemtabrutinib in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nemtabrutinib in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nemtabrutinib in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Drug Details: Nemtabrutinib (ARQ-531)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (Cisplatin + Vinblastine Sulphate) in Metastatic Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cisplatin + Vinblastine Sulphate) in Metastatic Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cisplatin + Vinblastine Sulphate) in Metastatic Pancreatic Cancer...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (Cisplatin + Vinblastine Sulphate) in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cisplatin + Vinblastine Sulphate) in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cisplatin + Vinblastine Sulphate) in Solid Tumor Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Apatinib Mesylate in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Apatinib Mesylate in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Apatinib Mesylate in Triple-Negative Breast Cancer (TNBC) Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Levonadifloxacin in Gram-Negative Bacterial Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Levonadifloxacin in Gram-Negative Bacterial Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Levonadifloxacin in Gram-Negative Bacterial Infections Drug Details: Levonadifloxacin (Emrok) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Elenagen in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Elenagen in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Elenagen in Gastric Cancer Drug Details: Elenagen is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DAC-002 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DAC-002 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DAC-002 in Triple-Negative Breast Cancer (TNBC) Drug Details: DAC-002 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AGENT-797 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AGENT-797 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AGENT-797 in Solid Tumor Drug Details: AGENT-797 is under development for...
Testimonial
Your Drugs database is great, you can find all the information you want such as sales forecasts, countries, diseases, dates, clinical trials, and patent expiration. We are using this information to research the leading competitive products in our current project. In addition, we analyze the profiles of the leading products and use this information to set the differentiation profile of our own products and clarify our positioning. In terms of business forecasts, we are able to provide more objective figures by using the Drug Forecast and Market Analysis report series. The analysis of product share by disease (series of Drug Forecast and Market Analysis reports) is used for business feasibility assessment.”
The ability to evaluate or provide information on PJs in R&D from both product and disease perspectives (it is difficult to find a database that can be used comprehensively for both), stands GlobalData out from other providers. The release of new functions such as Likelihood of approval (LoA) analysis, which was something I wanted but did not exist, shows that GlobalData have done a good job of researching the industry and developing services from the customer’s perspective which is another positive.
GlobalData’s COVID-19 Bulletin, which is sent out several times a week, provides the latest information on COVID-19 related vaccines and therapeutics and is used as background information.
“GlobalData provides extensive and comprehensive Pharma and Biotech data along with spectacular customer support. I use their drug, trial and company data on a daily basis to support our sales and marketing efforts.”
“As a global biopharma R&D strategy consultancy, we use the GlobalData Pharma Intelligence platform across a broad spectrum of topics, it provides all key data in one place”